Connect with us

Hi, what are you looking for?

New Products

PerkinElmer Launches New RGB LED Platform, Aculed, For Specialty and Medical Lighting Applications

COB Technology Delivers Superior Brightness, Excellent Color Mixing and Compact Size

Pfaffenhofen, Germany — September 16, 2005 – PerkinElmer Optoelectronics, a global technology leader in digital imaging, specialty lighting and optical detection technologies, today announced the availability of ACULED (All Color Ultrabright LED), its high power light source utilizing multi chip-on-board (COB) technology. PerkinElmer’s ACULED is a compact, multi-use LED (light emitting diode) designed for operation in a variety of specialty lighting applications including mood lighting, vision systems, architectural lighting and medical lighting. In February 2005, PerkinElmer acquired what is now known as PerkinElmer Elcos GmbH, a leading European manufacturer of custom LED solutions. ACULED is part of a high-performance, specialty lighting LED product series from PerkinElmer Elcos GmbH.

“In bringing PerkinElmer and Elcos together, we are already expanding our offering of differentiated technology solutions for new and existing customers,” said John Roush, President, PerkinElmer Optoelectronics. “We are delighted to be rolling out the ACULED RGB LED platform and are excited about the range of innovative specialty lighting and medical applications that can benefit from its excellent color mixing and brightness.”

PerkinElmer Elcos is offering ACULED Evaluation Kits so that customers can test the RGB LED platform with their particular applications.

PerkinElmer Optoelectronics is a global technology leader in digital imaging, specialty lighting and optical detection technologies. We provide applications-driven, integrated solutions to leading OEMs in Health Sciences and Industrial Science markets. More information about PerkinElmer Optoelectronics recent announcements is available at

Factors Affecting Future Performance

This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct.

A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) economic and geopolitical forces that may limit any continued or expected economic or end market strengthening or recoveries; (2) risks related to our failure to introduce new products in a timely manner; (3) the impact of our debt on our cash flow and investment opportunities: (4) our ability to comply with financial covenants contained in our credit agreements and our debt instruments: (5) a delay in resolution of the Company’s tax audits and an adverse determination by the Internal Revenue Service with respect to the Company’s tax audits; (6) cyclical downturns continuing to affect several of the industries into which we sell our products; (7) our ability to adjust our operations to address unexpected changes; (8) our ability to execute acquisitions and license technologies and successfully integrate acquired businesses and licensed technologies into our existing business; (9) the loss of any of our licenses that may require us to stop selling products or lose competitive advantage; (10) competition; (11) regulatory compliance; (12) regulatory changes; (13) our failure to obtain and enforce intellectual property protection; (14) our defense of third party claims of patent infringement and our ability to realize the full value of our intangible assets; (15) other factors which we describe under the caption “Forward-Looking Information and Factors Affecting Future Performance” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Other Information

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Industrial Sciences markets to improve the quality of life. The Company reported revenues of $1.7 billion in 2004, has 10,000 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through or 1-877-PKI-NYSE.

Advertisement. Scroll to continue reading.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *


You May Also Like


ecoustics is a hi-fi and music magazine offering product reviews, podcasts, news and advice for aspiring audiophiles, home theater enthusiasts and headphone hipsters. Read more

Copyright © 1999-2024 ecoustics | Disclaimer: We may earn a commission when you buy through links on our site.

SVS Bluesound PSB Speakers NAD Cambridge Audio Q Acoustics Denon Marantz Focal Naim Audio RSL Speakers